|Bid||17.11 x 300|
|Ask||17.27 x 100|
|Day's Range||16.96 - 17.54|
|52 Week Range||15.22 - 51.51|
|PE Ratio (TTM)||-2.80|
|Dividend & Yield||1.10 (6.43%)|
|1y Target Est||N/A|
Teva Pharma (TEVA) and Nuvelution inked a deal to accelerate the development of Austedo (deutetrabenazine) tablets for the treatment of tics associated with Tourette syndrome.
A bipartisan group of states investigating the opioid painkiller industry and the causes of widespread addiction have demanded fresh documents from drugmakers and distributors.